Literature DB >> 16541367

Molar tooth sign and superior vermian dysplasia: a radiological, clinical, and genetic study.

S Romano1, N Boddaert, I Desguerre, L Hubert, R Salomon, D Seidenwurm, N Bahi-Buisson, R Nabbout, P Sonigo, S Lyonnet, F Brunelle, A Munnich, P de Lonlay.   

Abstract

We have identified a group of 13 patients with a homogeneous radiological pattern at MRI consisting of the molar tooth sign (MTS) and superior vermian dysplasia. The patients represent a relatively heterogeneous clinical group with variable severity of developmental delay, ataxia, hypotonia, and apnea. Careful examination of MRI prompted us to split our series of patients into two groups, based on IVth ventricle dilatation. In 4/13 patients the IVth ventricle was judged to be dilated and those patients were less severely affected while most clinically affected patients had a normal IVth ventricle. DNA samples of blood leukocytes from 6/13 consanguineous patients were genotyped using polymorphic markers encompassing the Joubert syndrome loci. We therefore sequenced AHI1 located in 6q23 in two patients who were homozygous at the locus and in four sporadic cases. Only one homozygous nonsense mutation was identified. Clinically, the patient exhibiting the AHI1 mutation was the most severely affected child with a profound encephalopathy, major hypotonia, ataxia, Leber congenital amaurosis, and normal IVth ventricle at the MRI. The present study suggests that the syndrome associating MTS and dysplasia of the superior vermis of the cerebellum is a clinically and genetically heterogeneous entity and that Jouberin (AHI1) mutations account for a marginal fraction of patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16541367     DOI: 10.1055/s-2006-923838

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  8 in total

1.  Neurological picture. Mid-brain molar tooth sign: expanding the clinical spectrum.

Authors:  J N Panicker; B Jyothi; K P Sreekumar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01       Impact factor: 10.154

2.  MRI findings in Joubert syndrome.

Authors:  Suhil A Choh; Naseer A Choh; Shabir A Bhat; Majid Jehangir
Journal:  Indian J Pediatr       Date:  2009-01-05       Impact factor: 1.967

Review 3.  Clinical and molecular features of Joubert syndrome and related disorders.

Authors:  Melissa A Parisi
Journal:  Am J Med Genet C Semin Med Genet       Date:  2009-11-15       Impact factor: 3.908

4.  Mid-brain molar tooth sign: expanding the clinical spectrum.

Authors:  J N Panicker; B Jyothi; K P Sreekumar
Journal:  BMJ Case Rep       Date:  2009-02-18

5.  The Meckel-Gruber syndrome gene, MKS3, is mutated in Joubert syndrome.

Authors:  Lekbir Baala; Stephane Romano; Rana Khaddour; Sophie Saunier; Ursula M Smith; Sophie Audollent; Catherine Ozilou; Laurence Faivre; Nicole Laurent; Bernard Foliguet; Arnold Munnich; Stanislas Lyonnet; Remi Salomon; Ferechte Encha-Razavi; Marie-Claire Gubler; Nathalie Boddaert; Pascale de Lonlay; Colin A Johnson; Michel Vekemans; Corinne Antignac; Tania Attie-Bitach
Journal:  Am J Hum Genet       Date:  2006-11-15       Impact factor: 11.025

6.  Identification of a novel ARL13B variant in a Joubert syndrome-affected patient with retinal impairment and obesity.

Authors:  Sophie Thomas; Vincent Cantagrel; Laura Mariani; Valérie Serre; Ji-Eun Lee; Nadia Elkhartoufi; Pascale de Lonlay; Isabelle Desguerre; Arnold Munnich; Nathalie Boddaert; Stanislas Lyonnet; Michel Vekemans; Steven N Lisgo; Tamara Caspary; Joseph Gleeson; Tania Attié-Bitach
Journal:  Eur J Hum Genet       Date:  2014-08-20       Impact factor: 4.246

Review 7.  Mutation spectrum of Joubert syndrome and related disorders among Arabs.

Authors:  Salma Ben-Salem; Aisha M Al-Shamsi; Joseph G Gleeson; Bassam R Ali; Lihadh Al-Gazali
Journal:  Hum Genome Var       Date:  2014-11-06

8.  Arl13b Interacts With Vangl2 to Regulate Cilia and Photoreceptor Outer Segment Length in Zebrafish.

Authors:  Ping Song; Lynn Dudinsky; Joseph Fogerty; Robert Gaivin; Brian D Perkins
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-08-01       Impact factor: 4.799

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.